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1. Introduction
In contemporary regenerative concepts the combination of multipotent cells and individual‐
ized scaffolds holds great promise. Adult stem cells with their regenerative and proliferative
characteristics are a very adaptable cell resource for tissue regeneration.
From the support of neuronal healing processes after traumatic lesion to clinical application
in plastic surgery especially adult mesenchymal stem cells have already proven their opera‐
tional capability with good experimental as well as clinical success.
Human adipose derived stromal cells represent a group of mesenchymal stromal cells that
come with certain advantages in terms of regenerative medicine: the cells are easily and-if
necessary-repeatedly harvested, i.e. by liposuction, without leaving disfiguring scars and the
cells occur in abundance, thus a relevant amount of cells can be acquired quickly. The term
‘plasticity’ describes the potency of adipose derived cells, to cross-differentiate across their
original germ layer into cell lineages of non-mesenchymal origin. A feature that possibly opens
new vistas in regenerative tissue design.
Their special charm lies not only in their differentiating ability but in their secretory properties
also, that seem to be able to further support angiogenesis, inflammation and its regulation or
matrix remodelling processes.
This survey aims to present the current state of adult stem cell application in regenerative
concepts. With special regard to adipose-derived cells the chances and pitfalls of the appliance
of these cells are illuminated.
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2. Stem cells in regenerative medicine — Established strategies
When talking about stem cell biology one has to define and to confirm the characteristics of
this special cell population in each setting. Genuine stem cells distinguish themselves by
typical biological features.
Stem cells are able to renew themselves by symmetrical division; this cell division produces
two identical copies (daughter cells) from one original cell. During asymmetrical division one
of the originated cells becomes the aforementioned identical daughter cell, whereas the second
cell alters its cytological profile and starts irretrievably the differentiation towards a certain
specialized cell type.
Figure 1 illustrates symmetrical and asymmetrical stem cell division.
Figure 1. Symmetrical and asymmetrical stem cell division [1]
Stem cells provide a supply of progenitor cells, which are able to give rise to tissues from their
original dermal layer or, especially when talking about embryonic stem cells (ESC), to tissues
from all three different dermal layers. The ability to differentiate beyond the original cellular
derivation means true pluripotency. In contrast, adult stem cells, harvested for example from
bone marrow or the liver, are capable to generate specialized cells and tissues of their original
germ layer; this ability to bring forth cells similar to their embryonic origin is called multipo‐
tency. The plasticity of adult stem cells, the potential to differentiate beyond their original germ
layer in a multilineage development is discussed controversially in current literature for they
have not been successful in producing veritable offspring after injection into a tetraploid
blastocyst in a mouse model, so far [2].
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A well defined panel of surface markers characterizes stem cells as multi-or pluripotent cells
and separates them from other cell entities. Morphologically, for example multipotent adult
cells appear as spindle-shaped, fibroblast-like cells with fine tails. In the presence of other cell
populations the cells become more round, similar to cobblestones.
Yet, a morphological description alone is not able to identify the cells due to their similarity to
other cells, i.e. to fibroblasts.
The immunohistochemical evidence or the typical lack of characteristic surface markers
defines the cells under scrutiny as multi-or pluripotent cells. It is important to acknowledge
that the expression profile of the respective cell type is dynamic and might alter during under
cultivation and passaging.
Prominent defining surface markers of different human stem cells are summarized in Table 1.
ESC MSC ADSC
positive
SEA-3, SSEA-4, (), TRA-1-60, TRA-1-81,
alkaline phosphatase, GTCM-2
negative
SSEA-1
positive
CD105, CD90, CD 271, CD73
negative
CD34, CD45, CD14 or CD11b, CD79a
or CD19, MHC-II molecules, mainly
HLA-DR
positive
CD13, CD29, CD44, CD49, CD90,
CD105, CD106, CD166, Fibronectin,
aSMA, Vimentin, Collagen-1
negative
CD 31, CD45, CD 117, CD133, HLA-
DR, STRO-1, Lin, HLA II
Table 1. Surface markers of different adult stem cells [3,4]
To define stem cell criteria in a cell population in short the cells in question have to show the
capacity of self-renewal, they have to able to survive and proliferate long-term and the
unfractioned plastic-adherent cell population has to show multipotency [5].
In many scientific constellations different groups of pluri-and mulitpotent cells have proven
their effectiveness. There is a great variety of disorders in which stem cell therapy in different
applications might emerge as promising therapeutic strategy.
Table 2 summarizes cell lines and corresponding diseases where stem cell therapy is under
investigation.
Bai et al. investigated the effectiveness of adipose tissue derived pluripotent cells on cardiac
function after acute myocardial infarction in an in vivo design and were able to show that in
severe combined immunodeficient mice not only the cultivated cells but also the freshly
harvested and transplanted cells showed significant positive effect on myocardial regeneration
and cardiac function after local injection to the peri-infarct region [6].
Another prominent example is the application of bone marrow derived mesenchymal stem
cells in the therapy of retinal degeneration. In a rat model of retinal dystrophy the subretinal
or intravitreal transplantation of human bone marrow derived stem cells led to a significant
amelioration of the retinal function, whereas the effect in the subretinal injection group was
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more permanent [7]. Both examples underline the potential of these cells, even if many issues
remain unaddressed so far and a clinical application needs much more supportive data.
Tissue type Cell lineage Disease application
Endocrine Islet beta cells Diabetes
Blood Lymphoid cells
Erythrocytes
Immune deficiencies
Sickle cell anaemia
Liver Hepatocyte Liver failure
Renal Podocytes and tubular cells Acute and chronic renal failure
Neural Oligodendrocyte
Dopamine neuron
Motor neuron
Spinal cord injury
Parkinson’s disease
Motor neuron disease
Muscle Skeletal muscle Muscular dystrophy
Eye Retinal epithelium Retinal degeneration
Cardiovascular Cardiomyocyte
Endothelial
Myocardial infarction
Stroke
Ischaemic limb disease
Table 2. Tissues, cell lines and diseases
Different populations of pluripotent cells could exert their therapeutic efficacy in animal
models of meniscus and lung injury as well as in clinical studies of osteogenesis imperfect [8,
9, 10].
3. Adult stem cells: Their pros and cons
Stem cells derived from two different origins are investigated and applied successfully in many
scientific settings and some clinical strategies: one source, the most prominent and versatile
group of differentiating cells are human embryonic cells. The advantages of these cells are their
ability proliferate stably over many passages in in-vitro settings and their potential to differ‐
entiate into many different cell types derived from each one of the three embryonic germ layers:
the endo-, meso-and ectoderm layer [11].
This true pluripotency defines the unique attractiveness of these cells especially in regenerative
concepts that aim to replace complex anatomical structures. The harvesting of embryonic cells
nevertheless remains problematic and has been the reason for controversial ethical and forensic
debate: human embryonic stem cells are derived from cells of the blastocyst stage of embryos;
the embryos in question generally are derived from in vitro fertilization treatment and not
used for implantation for different motives; to date over 1000 immortal hESC cell lines are
reported.
Cells and Biomaterials in Regenerative Medicine106
The process of harvesting and isolating embryonic cells is strictly regulated and under religious
control. This reasonable and necessary limitation of the accessibility to the pluripotent cells
complicates their use in clinical research. In addition to that, transplanted hESCs often cause
strong immunorejection and as a result to their proliferative activity tend to cause neoplasia
i.e. teratoma [12]. Despite the controversies, in few clinical trials dealing with spinal cord
injuries, ECs are applied successfully: transplanted embryonic stem cell-derived glia cells,
which are capable of producing myelin, were able to redevelop damaged spinal cord tissues
in rodents with consecutive improved motoric functionality; these cells are utilised and studied
in patients with complete subacute spinal cord injury to date (A Phase 1 Safety Study of
GRNOPC1 in Patients With Neurologically Complete, Subacute, Spinal Cord Injury [clinical
trial]. ClinicalTrials.gov registration number: NCT01217008. Accessed at http://clinicaltri‐
als.gov/ct2/show /NCT01217008 on 11 June 2011.). The safety and tolerability of ECS derived
retinal cells are investigated in patients with advanced macular degeneration, a degenerative
disease that threatens the eyesight of millions of patients worldwide (A Phase I/II, Open-Label,
Multi-Center, Prospective Study to Determine the Safety and Tolerability of Sub-retinal
Transplantation of Human Embryonic Stem Cell Derived Retinal Pigmented Epithelial (MA09-
hRPE) Cells in Patients With Advanced Dry AMD [clinical trial]. ClinicalTrials.gov registration
number: NCT01344993. Accessed at www.clinicaltrials.gov/ct2 /show/NCT01344993 on 11
June 2011.).
Somatic or adult stem cells, the other source of differentiating cells, can be harvested as not-
differentiated cells between surrounding specialized cells in the mature organism from various
tissues or fluids without or with only little donor site morbidity. The difficulty of embryonic
cell harvesting or handling does not occur.
In therapeutic concepts the use of autologous cells provides the base of personalized therapy.
Their function in the embryo as well as in the adult organism is to replace and repair damaged
or aged cells or tissues: this concept becomes imminent regarding the regenerative potential
of the epidermis with its typical cell-based renewal cycle or the regenerative properties of the
liver after damage or resection.
The advantage of these mature cells is their capacity to differentiate into various specialized
cells and tissue types: mesenchymal stem cells from the bone marrow are able to develop into
different cell types within the limits of their original blastodermic layer, i.e. osteoblasts or
chondrocytes. Multilineage developmental or plasticity describes the stem cells’ potential to
overcome the histological limitations of their initial germ layer and their capacity to differen‐
tiate into progenitor cells and ultimately into cell types of another origin. This promising
attribute of adult stem cells is discussed controversially in current literature:
Krampera et al. compared adult stem cells from different origins for their study: in an in vitro
setting the authors were able to induce an ectodermic differentiation of MSCs from bone
marrow, fat, spleen and thymus into neuron-like cells [13]. Ning et al. described in 2009 an in
vivo endothelial differentiation of adipose tissue-derived stem cells under the influence of
Fibroblast Growth Factor 2 (FGF2) and other growth and proliferation factors in an animal
model. In the presence of FGF2 the observed ADSCs proliferated faster, expressed endothelial
surface markers as CD31 or von Willebrand Factor (vWF) and formed tube-like formations in
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matrigel [14]. Following these findings a cross germinal differentiation of adult stem cells –
with the support of growth of differentiation factors – seems feasible.
There are several similar investigations to support these findings; many other authors come
to the conclusion that this cross-germinal specialization cannot be observed reproducibly.
Especially the biological functionality of the differentiating cells is questioned critically.
In a clinical context, the capacity of adult stem cells to cross their germinal borderline remains
unclear so far; there is particularly no sufficient and finally convincing in-vivo data to support
the hypothesis.
Adult stem cells are detected in different tissues:
Mesenchymal stromal or stem cells (MSCs) are fibroblast-like shaped cells and appear
ubiquitously in the human organism; they seem to originate from perivascular or adventitial
tissue. They have the potential of multilineage differentiation and seem to exert numerous
paracrine effects: by secreting different growth and signalling factors they seem to be able to
modulate angiogenesis, (anti) inflammation or apoptosis.
The first MSCs described were bone marrow derived cells [15]: they are harvested from bone
marrow aspirates. Their cultivation, functional characterization and differentiation behaviour
has been investigated since the 1970s. Under standard culture conditions they have to be able
to specialize into osteoblasts and chondrocytes.
Adipose derived stromal cells (ADSCs) come with many advantages: their harvest is much
easier and safer than the isolation of bone marrow. One is able to produce the cells in larger
amounts and the cells can be isolated repeatedly from the same donor region. The isolation
and characterization is performed without difficulty and has often been described in literature.
Figure 2 gives a survey of the isolation of hADSCs.
Another interesting source of adult stem cells is the dental pulp stem cells (DPSCs). The
probably most attractive feature of these cells that develop from the neural crest is their easy
approachability from removed (wisdom) teeth as a by-product of the necessary surgery [16].
Due to their cytological similarity to bone marrow derived stem cells, these dental derived cells
are under special investigation concerning not only repair or replacement of dental structures
but in musculoskeletal regeneration also. During their characterisation in vitro it could be shown
that DPSCs – compared to bone marrow derived cells for – show striking similarity to neuro‐
glia cells and differentiated into neural and endothelial cells reproductively [17].
It has been possible to reprogramme dental pulp cells after third molar removal to induced
pluripotent cells (iPS) that differentiated in vitro and in-vivo expressing cell and tissue types
from all three germ layers. Even the typical formation of teratoma could be observed [18].
In mouse models of myocardial infarction and hind limb ischemia the therapeutic potential of
endothelial and smooth muscle cells derived from DPSC induced pluripotent cells has been
demonstrated [19]. These investigations encourage further scientific work with dental pulp
derived cells, which are gained in many cases as a by-product of a necessary tooth removal;
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in future concepts the dental pulp cells from third molars might be preserved and stored for
later use in cell based autologous tissue regeneration.
To combine the good accessibility of adult cells with the excellent differentiating potential
another cell source was to be established. Induced pluripotent cells (iPS) surmount the problem
of limited access: the cells, for example skin fibroblasts, can be harvested (repeatedly) after
informed consent in the mature organism from various tissues as adult cells with differenti‐
ating capacity. Therefore they prevail the difficulty of immunoreactivity: they can be harvested
autologously. By inducing certain surface/ interaction markers retrovirally, among others
Sox2, c-Myc, the so-called Yamanaka factors, these cells forget their initial programming and
regress to an earlier precursor stage with enhanced, ES cell-like differentiating properties.
Similar to ECS they are capable of unlimited self-renewal in vitro.
The iPS cells show very good proliferative activity; this feature comes with the induction of
neoplasia after transplantation, similar to embryonic stem cells.
Their potential and special charm lies in the fact, that with the help of this technique it is
generally feasible to isolate an individual cell line from almost every donor. This cell line might
be the basis of cell pool, from which many different functional cell and tissue type can be
generated autologously for individualized regenerative concepts. In addition iPS cells are used
for the construction of disease specific cell and tissue models. With these the potential of
therapeutic strategies can be explored.
Figure 3 illustrates the experimental process.
Figure 2. The preparation and isolation process, RT=room temperature, SVF=stromal-vascular cell fraction [3]
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Figure 3. iPS cells as models of different diseases [20, 21]
The harvest, isolation and application of somatic or adult stem cells provide the potential for
personalized regenerative concepts. The application especially of autologous cells comes with
the advantage of avoiding immunorejection and has verified its prospective in different clinical
concepts.
4. Adipose-derived cells vs. bone marrow-derived cells
Human adipose derived stromal cells (hADSCs) are localized in different fatty tissues as
subcutaneous, visceral and omental fat. Morphologically these cells appear typically as
spindle-shaped. Their harvesting and isolation can be easily performed with minimal invasive
approach under local anaesthesia with minimal tissue damage and without excessive scarring,
for example by liposuction or –aspiration, if necessary the collect can be repeated without
difficulty. The cells can be harvested in amounts that up to 500 times higher than mesenchymal
stromal cells from other localizations. This feature comes with the advantage that the cells
could be implanted at a therapeutic amount without a preparing culturing and expansion
phase; thus, adverse culture effects that might impair their biological function and effective‐
ness can be avoided [22].
In many investigations it was possible to show that the adipose derived cells are able to
differentiate within their original embryonic germ layer to chondrocytes or myoblasts. In
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addition some authors state that a capacity for differentiation beyond the cytological restric‐
tions of the mesoderm to neuronal and endothelial cells is possible. Rehman et al. among others
described the potential of adipose derived cells for endothelial and macrophage differentiation
[23]. These traits make adipose-derived cells an ideal cell source for personalized regenerative
concepts including bone or chondral tissue. In addition to that, adipose-derived tissue
represents an enormous reservoir of potentially angiogenic cells. Their prospective in thera‐
peutic (neo-)vascularization is not yet fully elucidated.
Table 3 gives a survey of modulating factors that initiate the respective differentiation of
ADSCs.
Adipogenic specialization Insulin, IBMX, dexamethasone, rosiglitazone,
indomethacin
Osteogenic specialization 1,25-dihydroxy-cholecalciferol, beta-glycerophosphate,
ascorbic acid
Neurogenic specialization EGF, FGF, 5-azacytidine
Table 3. Selection of growth factors that support the various differentiations of hADSCs, EGF: epidermal growth
factor; FGF: fibroblast growth factor, BMX: 3-isobutyl-1-meyhylxanthine; IGF: insulin-like growth factor, [24]
In in-vitro settings the culture with certain supplements und defined conditions led to the
assumption, that a differentiation of ADSCs to hepatocytes of beta cells of the langerhans islets
might be feasible, hinting to a probable autologous cell based approach to chronic liver failure
or diabetes mellitus. However, these interesting attempts are not ready for therapeutic
application yet [25, 26].
Bone marrow derived mesenchymal stromal cells (BM-MSCs) were the first pluripotent adult
cells to be detected and investigated and therefore are characterized adequately. Bone marrow
derived MSCs are gained from bone marrow aspirates, a painful clinical procedure that comes
with potential donor site morbidity as an impaired sensitivity of the lateral thigh or pelvis
fracture. The output of pluripotent cells is relatively small; only 0.001%-0.01% of the nucleated
bone marrow cells can be expected to have differentiating potential, with decreasing percent‐
age in elder donors [22]. BM-MSCs have been applied in various in vitro settings, in animal
models and in some clinical trials.
When comparing adipose-and bone marrow derived cells, one has to regard the immunophe‐
notype. The expression of surface markers on both cell types is widely identical. Whereas
adipose derived cells tend to express CD34 especially in early stages, bone marrow derived
cells and MSCs from other sources do not express this surface marker [27].
Furthermore there is some hint that bone marrow derived MSCs show a significantly reduced
proliferation rate compared to other adult pluripotent cells as adipose derived cells or
umbilical cord cells [28]. This question is discussed controversially though; harvesting,
isolation and culture protocols or conditions as media or various supplements might be
responsible for enhanced or reduced proliferation rates – independent from the cell source.
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The question of superior differentiation capacity is debated controversially also. There are
many investigations supporting the thesis that the one or the other cell type might be superior
in differentiating to an adipogenic or osteogenic direction or they detect no difference at all.
In this case, too, the impact of special culture conditions as cause of the different findings has
not been ruled out fully.
Finally, the bone marrow and adipose derived cells seem to exert different immunomodulatory
effects on their host tissue. In different in vitro studies ADSCs seem to have a more pronounced
suppressive effect on the immune response than BM-MSCs. Adipose derived cells were more
efficient to inhibit the maturation of dendritic cells and in stimulating the secretion of the
immunomodulatory cytokine IL 10 [29, 30].
The analysis of the respective gene expression profile of ADSCs and BM-MSCs indicated that
a differential expression of about 13% of the studied genes differentiates both cell populations
on gene level. It was not possible to define certain key markers that clearly identify their origin.
Different cell passages or varying culture conditions, too, influence the expression profile [31].
5. Current concepts of stem cell supported tissue engineering
The first reported success of the clinical use of autologous differentiating cells in regenerative
medicine was the successful treatment of traumatic calvarian defects with a combination of
autologous iliac bone, adipose derived stromal cells and fibrin in a degradable scaffold leading
to bone formation and good clinical regeneration of the impaired scull [32].
Clinical trials with small patient groups report, that during the treatment of chronic perianal
fistula of Crohn patients, a local therapy of the affected area with autologous ADSCs, in
combination with fibrin glue, seems to effect a higher healing rate than many other therapeutic
strategies [33, 34].
Especially in plastic surgery clinical concepts based on the distinctive properties of adipose
derived stem cells are established; actually the cells’ potential has been discovered by plastic
surgeons [35].
One clinical challenge in plastic surgery is the surgical approach to chronic wounds as diabetic
ulcers or skin defects after radiation due to the impaired vascularisation of the affected area.
Allogeneic dermis or collagen scaffolds are cultivated with adipose derived pluripotent cells
that lead to good clinical results, avoiding the accompanying scarring and donor site morbidity
of local flap surgery. The procedure can easily be repeated in larger and deeper defects [36].
Injection of autologous adipose derived stromal cells is effective in the treatment of arterial
clotting after filler injection in the face for augmentation purposes. When this complication
happens, the area in question becomes sensitive and painful due to the hypoxia of the affected
tissue. The arterial obstruction has to be overcome within 4-5 days to avoid tissue necrosis. In
case reports it has been described that the injection of autologous ADCs results in reduced
ischemia and immediate neo-vascularisation. In Europe the first clinical trial with ADSCs in
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the treatment of cardiovascular diseases as acute myocardial infarction or chronic heart failure
have started.
Dental pulp derived stem cells have been studied and applied in regenerative concepts
concerning the tooth structures particularly. In an animal model Iohara et al. demonstrated
the entire regeneration of the histologically complex pulp tissue including neuro-and vascu‐
logenesis after pulpectomy supported by autologous PDSCs transplantation [37].
According to their original repair and renewal function autologous DPSCs have been einge‐
setzt to replace dentin. In a porcine model direct pulp capping has been performed using
autologous DPSCs together with a synthetic restaurative dental material (beta-tricalcium
phosphate); in the follow up control the effective dentin regeneration was demonstrated [38].
The aim to completely replace a missed tooth requires a complex communication, interaction
and vice-versa induction of mesenchymal cells and epithelial cells from the oral cavity;
different investigative settings aim to orchestrate this complex interaction. Ikeda et al. were
able to complete the bioengineering of a primordial tooth that has been inserted in the oral
cavity and developed roots and really erupted into the oral cavity [39]. Beyond the dental
structures DPSCs have shown their capacity for osteogenic differentiation in vitro as well as
in in-vitro trials. Dental pulp derived cells were used among others combined with beta
tricalcium phosphate scaffolds in critical size defects in rat calvaria. Annibaldi et al. reported
in their preliminary data a trend to increased bone density and mineralisation in the presence
of the DPSCs [40].
Beyond their potential concerning hard tissue regeneration, dental pulp derived cells were
under investigation in terms of neurological and endocrinological issues also. The hopeful
results report an improved and accelerated functional regeneration after focal cerebral
ischemia and therapeutic local transplantation of DPSCs; especially the impact of secreted
mediators on the repair mechanisms seems to cause the observed effects [41]. Not only a
differentiation to hepatocyte-like cells with the ability to store glycogen and to produce urea
but also islet-like cells being able to release insulin glucose-dependently has been working out
in-vitro and in mice models [42, 43].
To date the most encouraging operational area for adult, especially adipose derived stem cells
are concepts of bone repair and regeneration. Especially the active physiological behaviour of
healthy bone tissue with its permanent remodelling to adapt to mechanical loading or its lack
or to accommodate the current nutrient supply makes this tissue an ideal point of application
for cell based intervention. Additionally, the therapy of bony critical size defects often comes
with clinical problems of tedious distraction, insufficient long-term osteosynthesis or donor
site morbidity after autologous bone grafting.
Current research therefore deals with interventional concepts that combine the differentiating
precursor cells from adipose tissue with the enormous paracrine effect of these cells, secreting
a plethora of proliferation, growth and differentiation factors and thus activating not only the
regenerative potential of the resident tissue but also attracting circulating precursor cells.
Structural base of the most regenerative approaches is still a 3D scaffold to support the homing
of the proliferating cells. Not only are the mechanical properties of these scaffolds of impor‐
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tance, their composition affects the biology of the cells also: Marino et al. were able to depict,
that the osteogenic differentiation of human adipose derived stem cells onto a porous beta-
tricalcium phosphate (beta-TCP) matrix was triggered by the scaffold alone without the use
of differentiative media [44]. This effect might be enhanced by modern composite scaffolds:
akermanite scaffolds, consisting of calcium-, magnesium-, and silicon-containing ceramic
show improved stability and better degradation. In addition they seem to positively influence
the functionality of differentiating cells by inducing their calcium deposition [45, 46].
6. Future prospect
In different experimental settings the transplanted pluripotent cells do not exert their regen‐
erative potential by actually differentiating and replacing damages tissue but exert their effects
by secreting growth, proliferation and differentiation factors and thus in a paracrine way or
by cell-cell interaction.
In terms of stem cell science many biological and technical questions remain unanswered so
far and years of intense research lay ahead before autologous pluripotent cells become a
standard tool in clinical routine.
The current restrictions of embryonic stem cell research are necessary to avoid abuse but the
promising, steadily growing comprehension about adult stem cells and induced pluripotent
cells with their ability to regain their original differentiating potential seem to hint to the fact
that these cells might be the target of interest in future regenerative concepts in personalized
medicine.
The challenge of the coming decade of stem cell research will have to deal with safety issues,
the problem to reliably avoid oncogenic growth and to develop reproducible, secure and
payable concepts of cell isolation, culturing, (re-) programming and storage. There have to be
protocols for the autologous transplantation to the region of interest and techniques to improve
cell homing.
Despite many unanswered questions the future of many regenerative concepts will be
supported by the potential of differentiating cells.
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